Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz

Executive Summary

Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not

Related Content

Neurontin, Rebetol Generics Could Be Affected By “Shared Exclusivity” Ruling
Omeprazole Generic Will Stay: Schwarz Does Not Infringe Prilosec Patent
Schwarz Omeprazole On Track For $1 Bil.; Transforming Event For Company?
Schwarz Omeprazole Launch Is Limited By Manufacturing Capacity
Andrx Altocor Sales Force Expands 50%; Generic Prilosec Charge Is $41 Mil.
Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm
Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation
GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity
Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts